StockNow
Calendar
Log in
U.S. Markets

Genmab (GMAB) and AbbVie (ABBV) announce Epcoritamab in combination with R-CHOP demonstrates statistically significant improvement in Progression-Free Survival in Patients with newly diagnosed Diffuse Large B-Cell Lymphoma

StockNow breaking-news AI analysis

Genmab and AbbVie announced improved progression-free survival with epcoritamab plus R-CHOP in newly diagnosed diffuse large B-cell lymphoma; the supplied record lacks supporting numerical and study details.

2 stocks
GMABGenmab A/S ADS$38.78Current priceABBVABBVIE INC.$263.68Current price

What do investors think?

Curious what other investors think?Log in to see reactions and join the conversation.
Log in to view reactions

StockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.

Today's market highlights

A selection of stories drawing attention in the market.

See more
Commodities

Yemeni Houthis hit Saudi Arabia's Ras Tanura refinery (550k BPD) with missiles, Sabereen reports

Geopolitics

UKMTO has received a time-delayed report of a warning that an inbound LNG tanker was struck by an unknown projectile in the Strait of Hormuz

Geopolitics

Explosion reportedly heard in Riyadh, Saudi Arabia, reports Sabereen News